Inicio / Precios / Inyección intravítrea de ranibizumab

Inyección intravítrea de ranibizumab

Oftalmología aproximadamente CNY 5500-6500

Descargo de responsabilidad: Este sitio es una plataforma de servicios médicos; parte del contenido de la página es asistido por IA. La información sobre salud no constituye consejo médico. Si tiene alguna pregunta, consulte a un profesional de la salud. Ver más

Descripción

Procedimiento oftalmológico que consiste en la administración de ranibizumab directamente en el vítreo para inhibir el factor de crecimiento endotelial vascular (VEGF) en enfermedades retinianas como la degeneración macular asociada a la edad.

Usos Principales

Primary clinical use is intravitreal administration of ranibizumab (a recombinant humanized monoclonal antibody fragment) to inhibit vascular endothelial growth factor-A (VEGF-A) in the eye. Indications include: neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV). Treatment aims to reduce vascular leakage, inhibit abnormal blood vessel growth, stabilize or improve visual acuity, and prevent disease progression.

Rango Normal

Not applicable — anti-VEGF intravitreal injection (ranibizumab) is a therapeutic procedure, not a diagnostic laboratory test with quantitative biomarker values. There is no 'normal range' for ranibizumab concentration in clinical practice; dosing is standardized (0.5 mg/0.05 mL per injection), and systemic drug levels are not routinely monitored.

Valores Bajos - Posibles Causas

N/A — this is not a measurable serum or ocular fluid assay; 'low value' does not apply. However, subtherapeutic effect may result from: 1) Inadequate dosing frequency (e.g., extended dosing intervals beyond disease activity), 2) Poor drug penetration due to vitreous opacities or fibrosis, 3) Development of neutralizing anti-ranibizumab antibodies (rare), 4) Non-adherence to treatment protocol, 5) Underlying disease resistance (e.g., persistent VEGF-independent angiogenesis).

Valores Altos - Posibles Causas

N/A — no clinically defined 'high value' exists. Potential concerns related to excessive exposure include: 1) Off-label repeated injections without evidence-based justification, 2) Accidental overdose (e.g., dosing error — extremely rare with prefilled syringes), 3) Systemic absorption leading to elevated free VEGF inhibition (theoretical risk of hypertension or thromboembolism), 4) Concomitant use of other anti-angiogenic agents, 5) Pre-existing systemic conditions exacerbating anti-VEGF effects (e.g., uncontrolled hypertension, recent stroke).

inyección de ranibizumab inyección intravítrea terapia anti-VEGF

aproximadamente CNY 5500-6500

Contáctenos